British drugs group GlaxoSmithKline is planning to create a new £15bn FTSE 100 company by spinning out a subsidiary focused on treating HIV.Â
Viiv Healthcare is expected to attract a "significant" capitalisation due to its rapid growth according to chief executive Sir Andrew Witty.
ViiV's newest HIV medicines, Trumeq and Tivicay, have...